NY 303
Alternative Names: NY-303Latest Information Update: 22 Dec 2023
At a glance
- Originator NAYA Biosciences
- Developer NAYA Biosciences; ONK Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours